Synopsis
Synopsis
0
JDMF
0
KDMF
0
VMF
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Arechin
2. Chingamin Phosphate
3. Chloroquine Bis(dihydrogenphosphate) Dihydrate
4. Chloroquine Diphosphate
5. Chloroquine Diphosphate, (+)-isomer
6. Chloroquine Diphosphate, (+-)-isomer
7. Chloroquine Diphosphate, (-)-isomer
8. Delagil
9. Khingamin Phosphate
10. N(4)-(7-chloro-4-quinolinyl)-n(1),n(1)-diethyl-1,4-pentanediamine, Phosphate (1:2)
11. Resochin
12. Unspecified Phosphate Of Chloroquine Diphosphate
1. Chloroquine Diphosphate
2. 50-63-5
3. Resochin
4. Arechin
5. Aralen Phosphate
6. Chingamin Phosphate
7. Chloroquine Bis(phosphate)
8. Chloroquine Diphosphate Salt
9. Avloclor
10. Delagil
11. Chloroquine (phosphate)
12. Khingamin
13. Miniquine
14. Tanakan
15. Tanakene
16. Aralen Diphosphate
17. Gontochin Phosphate
18. N4-(7-chloroquinolin-4-yl)-n1,n1-diethylpentane-1,4-diamine Bis(phosphate)
19. Chloroquin Diphosphate
20. Nsc 14050
21. Ipsen 225
22. Chloroquinediphosphate
23. Mfcd00069852
24. 3377 Rp
25. 50-63-5 (diphosphate)
26. Sn 7,618
27. Nsc-14050
28. 6e17k3343p
29. Sn-7618
30. Wr-1522
31. Chingaminum
32. Alermine
33. H-stadur
34. Dsstox_cid_24681
35. Dsstox_rid_80393
36. Dsstox_gsid_44681
37. 1,4-pentanediamine, N(sup 4)-(7-chloro-4-quinolinyl)-n(sup 1),n(sup 1)-diethyl-, Phosphate (1:2)
38. Chlorochin Diphosphate
39. Tanakan (antimalarial)
40. 4-n-(7-chloroquinolin-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;phosphoric Acid
41. Dl-chloroquine Diphosphate
42. Ccris 1554
43. Sr-01000075548
44. Einecs 200-055-2
45. Wr 1522
46. Chloroquine Dihydrogen Phosphate (1:2)
47. Unikinon
48. Ai3-14952
49. Unii-6e17k3343p
50. Chloroquine Phosphate [usp:ban]
51. Chloroquindiphosphat
52. Chloroquini Phosphas
53. Prestwick_867
54. Aralen (tn)
55. Cas-50-63-5
56. Ncgc00015256-01
57. 7-chlor-4-(4-(diaethylamino)-1-methylbutylamino)-chinolindiphosphat [german]
58. 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline Phosphate (1:2)
59. N4-(7-chloro-4-quinolinyl)-n1,n1-dimethyl-1,4-pentanediamine Diphosphate Salt
60. Chloroquine Diphosphate,(s)
61. 1,4-pentanediamine, N4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, Phosphate (1:2)
62. N(4)-(7-chloro-4-quinolinyl)-n(1),n(1)-diethyl-1,4-pentanediamine, Phosphate (1:2)
63. 1,4-diamine Bis(phosphate)
64. Chloroquine Phosphate (usp)
65. Schembl40827
66. Chembl58510
67. Spectrum1500179
68. Chloroquine Diphosphate, Sulfate
69. Dtxsid7044681
70. Hms501e06
71. Hms1569n17
72. Hms1920o05
73. Hms2091c16
74. Hms2096n17
75. Hms3260l14
76. Hms3713n17
77. Bcp31956
78. Chloroquine Diphosphate [mi]
79. Tox21_110115
80. Tox21_202838
81. Tox21_500296
82. 7-chlor-4-(4-(diaethylamino)-1-methylbutylamino)-chinolindiphosphat
83. Ccg-39643
84. Chloroquine Phosphate [vandf]
85. S4157
86. Chloroquine Phosphate [mart.]
87. Akos004910410
88. Chloroquine Phosphate [usp-rs]
89. Chloroquine Phosphate [who-dd]
90. Chloroquine Phosphate [who-ip]
91. N4-(7-chloro-4-quinolyl)-n1,n1-diethyl-pentane-1,4-diamine; Phosphoric Acid
92. Quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-, Diphosphate
93. Tox21_110115_1
94. Cs-3811
95. Dt-0015
96. Lp00296
97. 1,4-pentanediamine, N4-(7-chloro-4-quinolinyl)-n',n'-diethyl-, (+-)-, Phosphate (1:2)
98. Quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, Phosphate (1:2)
99. Ncgc00015256-12
100. Ncgc00093746-01
101. Ncgc00093746-02
102. Ncgc00093746-03
103. Ncgc00260384-01
104. Ncgc00260981-01
105. Ac-12463
106. Chloroquine Phosphate [green Book]
107. Hy-17589
108. Sy021941
109. Chloroquine Phosphate [orange Book]
110. Chloroquine Phosphate [ep Monograph]
111. Chloroquini Phosphas [who-ip Latin]
112. Db-051808
113. Chloroquine Diphosphate Salt, Solid, >=98%
114. Chloroquine Phosphate [usp Monograph]
115. Eu-0100296
116. Ft-0602804
117. C 6628
118. D02125
119. D70732
120. 069c852
121. A828213
122. N4-(7-chloroquinolin-4-yl)-n1,n1-diethylpentane-
123. Sr-01000075548-1
124. Sr-01000075548-3
125. Sr-01000075548-5
126. Q27264629
127. F2173-1139
128. 7-chloro-4-[[4-(diethylamino)-1-methylbutyl]amino]quinoline Phosphate
129. 7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline Bis(phosphate)
130. 7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline Diphosphate
131. Chloroquine Phosphate, United States Pharmacopeia (usp) Reference Standard
132. N4-(7-chloro-4-quinolyl)-n1,n1-diethyl-1,4-pentanediamine Diphosphate
133. 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline Phosphate (1:2).
134. Chloroquine Phosphate, Pharmaceutical Secondary Standard; Certified Reference Material
135. Chloroquine Phosphate;aralen Phosphate;7-chloro-4-((4 Inverted Exclamation Mark -diethylamino-1-methylbutyl)amino)quinolinediphosphate
Molecular Weight | 515.9 g/mol |
---|---|
Molecular Formula | C18H32ClN3O8P2 |
Hydrogen Bond Donor Count | 7 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 8 |
Exact Mass | 515.1353167 g/mol |
Monoisotopic Mass | 515.1353167 g/mol |
Topological Polar Surface Area | 184 Ų |
Heavy Atom Count | 32 |
Formal Charge | 0 |
Complexity | 359 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
1 of 2 | |
---|---|
Drug Name | Chloroquine phosphate |
Drug Label | Chloroquine phosphate, USP is a 4-aminoquinoline compound for oral administration. It is a white crystalline powder; odorless; has a bitter taste, and is discolored slowly on exposure to light. It is freely soluble in water, practically insoluble in... |
Active Ingredient | Chloroquine phosphate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base; eq 150mg base |
Market Status | Prescription |
Company | Ipca Labs; Natco Pharma; Hikma Pharms; Impax Labs |
2 of 2 | |
---|---|
Drug Name | Chloroquine phosphate |
Drug Label | Chloroquine phosphate, USP is a 4-aminoquinoline compound for oral administration. It is a white crystalline powder; odorless; has a bitter taste, and is discolored slowly on exposure to light. It is freely soluble in water, practically insoluble in... |
Active Ingredient | Chloroquine phosphate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 300mg base; eq 150mg base |
Market Status | Prescription |
Company | Ipca Labs; Natco Pharma; Hikma Pharms; Impax Labs |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Antimalarials
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) (See all compounds classified as Antimalarials.)
Filaricides
Pharmacological agents destructive to nematodes in the superfamily Filarioidea. (See all compounds classified as Filaricides.)
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3926
Submission : 1980-07-31
Status : Inactive
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6425
Submission : 1986-06-11
Status : Inactive
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-12-09
Pay. Date : 2019-09-27
DMF Number : 34130
Submission : 2019-09-20
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-06-21
Pay. Date : 2019-06-14
DMF Number : 33067
Submission : 2019-02-20
Status : Active
Type : II
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0014
Address of the Firm :
NDC Package Code : 63850-8080
Start Marketing Date : 2018-03-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10472
Submission : 1993-09-10
Status : Inactive
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6425
Submission : 1986-06-11
Status : Inactive
Type : II
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3926
Submission : 1980-07-31
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-10-25
Pay. Date : 2013-07-15
DMF Number : 9235
Submission : 1991-07-02
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-21
Pay. Date : 2019-06-14
DMF Number : 33067
Submission : 2019-02-20
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10472
Submission : 1993-09-10
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-12-09
Pay. Date : 2019-09-27
DMF Number : 34130
Submission : 2019-09-20
Status : Active
Type : II
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
About the Company : Tenatra International was established as a proprietorship firm in 1999. It got off to a very good start, supporting clients in the United States, Mexico and Europe. As business opp...
About the Company : Atman Pharma Private Limited is a fully integrated pharmaceutical company that has distinguished itself as a leader in Bulk Drugs (API) marketing both domestically in India and ove...
About the Company : BOC Sciences is a brand of BOCSCI Inc. We leverage our wide spectrum of business in the fields of development, manufacturing, marketing, and distribution to help you make best-info...
About the Company : Dalian Richon Chem. Co., Ltd is a high-tech enterprise professionally involved in research and development, manufacturing process and sales service of pharmaceutical intermediates ...
About the Company : Ipca Laboratories, headquartered in Mumbai, India, is a prominent pharmaceutical enterprise established in 1949. Over the years, Ipca has emerged as a leading player in India's pha...
About the Company : Mangalam Drugs & Organics Limited started manufacturing APIs and intermediates in 1977 in Gujarat, India. It has a multi-product manufacturing facility and an in-house R&D lab reco...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
About the Company : Vital Group of companies is a leading Manufacturer and Exporter of Active Pharmaceutical Ingredients (API). Founded in 1999 Vital set up a unit for manufacturing for Quinine Salts ...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.
Lead Product(s): Tafenoquine Succinate,Chloroquine Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Kozenis
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Medicines for Malaria Venture
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 07, 2024
Lead Product(s) : Tafenoquine Succinate,Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
GSK and MMV Launch New Medicine to Prevent Plasmodium vivax Malaria Relapse
Details : Kozenis (tafenoquine) is the first single-dose, oral, hematin polymerization inhibitor co-administered with chloroquine for preventing P. vivax malaria relapse, launched in Thailand and Brazil.
Product Name : Kozenis
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2024
Details:
Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.
Lead Product(s): Chloroquine Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: Certara
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Certara
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Certara will support the DMTC led clinical trial by analyzing study data to develop mathematical models to understand viral time course and factors impacting drug exposure and prophylactic response.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 05, 2020
Details:
An international study named “CROWN CORONATION” aims to include up to 55,000 subjects and is designed to assess the effectiveness of multiple dose ranges of chloroquine to prevent SARS-CoV-2 infection in frontline healthcare workers.
Lead Product(s): Chloroquine Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 18, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rising Pharmaceuticals to Support Global Clinical Trial Conducted by the CROWN Collaborative
Details : An international study named “CROWN CORONATION” aims to include up to 55,000 subjects and is designed to assess the effectiveness of multiple dose ranges of chloroquine to prevent SARS-CoV-2 infection in frontline healthcare workers.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 18, 2020
Details:
Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.
Lead Product(s): Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Bayer AG
Deal Size: $1.1 million Upfront Cash: Undisclosed
Deal Type: Partnership April 21, 2020
Lead Product(s) : Chloroquine Phosphate,Azithromycin,Interferon Beta 1B
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Bayer AG
Deal Size : $1.1 million
Deal Type : Partnership
Details : Bayer and PHRI together will conduct two studies that will evaluate the safety and efficacy of different combination therapies including Bayer’s chloroquine and interferon beta-1b.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 21, 2020
Details:
Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Lead Product(s): Chloroquine Phosphate
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: US Government
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 19, 2020
Lead Product(s) : Chloroquine Phosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : US Government
Deal Size : Undisclosed
Deal Type : Partnership
Bayer Partners with U.S. Government on Major Product Donation to Fight Coronavirus
Details : Bayer is working with appropriate agencies on an Emergency Use Authorization for the drug’s use in the U.S.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 19, 2020
CAS Number : 86-98-6
End Use API : Chloroquine Phosphate
About The Company : Mangalam Drugs & Organics Limited started manufacturing APIs and intermediates in 1977 in Gujarat, India. It has a multi-product manufacturing facility and an i...
(4,7-Dichloroquinoline (4,7-DCQ)}
CAS Number : 86-98-6
End Use API : Chloroquine Phosphate
About The Company : Vital Group of companies is a leading Manufacturer and Exporter of Active Pharmaceutical Ingredients (API). Founded in 1999 Vital set up a unit for manufacturin...
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 40MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 40MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 40MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 40MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : TABLET
Dosage Strength : 250MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : TABLET
Dosage Strength : 250MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Injection
Dosage Strength : 40MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Injection
Dosage Strength : 40MG/ML
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 100MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 100MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 300MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 300MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Film Coated Tablet
Dosage Strength : 400MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 400MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name : Lariago
Dosage Form : INJECTION
Dosage Strength : 50MG/ML
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging :
Regulatory Info : Generic
Dosage : INJECTION
Dosage Strength : 50MG/ML
Brand Name : Lariago
Approval Date :
Application Number :
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 500MG
Packaging : Bottle
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Packaging : Bottle
Regulatory Info : Generic
Dosage : Tablet
Dosage Strength : 500MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 250MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 250MG
Brand Name :
Approval Date :
Application Number :
Registration Country : India
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
10 Nov 2022
Reply
20 Jun 2022
Reply
20 May 2020
Reply
16 Apr 2020
Reply
06 Apr 2020
Reply
04 Apr 2020
Reply
01 Apr 2020
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
94
PharmaCompass offers a list of Chloroquine Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Chloroquine Phosphate manufacturer or Chloroquine Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Chloroquine Phosphate manufacturer or Chloroquine Phosphate supplier.
PharmaCompass also assists you with knowing the Chloroquine Phosphate API Price utilized in the formulation of products. Chloroquine Phosphate API Price is not always fixed or binding as the Chloroquine Phosphate Price is obtained through a variety of data sources. The Chloroquine Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2)., including repackagers and relabelers. The FDA regulates 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). supplier is an individual or a company that provides 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). active pharmaceutical ingredient (API) or 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). finished formulations upon request. The 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers may include 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). API manufacturers, exporters, distributors and traders.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). DMF (Drug Master File) is a document detailing the whole manufacturing process of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). active pharmaceutical ingredient (API) in detail. Different forms of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). DMFs exist exist since differing nations have different regulations, such as 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). DMF submitted to regulatory agencies in the US is known as a USDMF. 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). USDMF includes data on 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2).'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers with USDMF on PharmaCompass.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP of the European Pharmacopoeia monograph is often referred to as a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). Certificate of Suitability (COS). The purpose of a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). to their clients by showing that a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP has been issued for it. The manufacturer submits a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP (COS) as part of the market authorization procedure, and it takes on the role of a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP holder for the record. Additionally, the data presented in the 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). DMF.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers with CEP (COS) on PharmaCompass.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). written confirmation (7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). WC) is an official document issued by a regulatory agency to a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). manufacturer, verifying that the manufacturing facility of a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). APIs or 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). finished pharmaceutical products to another nation, regulatory agencies frequently require a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). WC (written confirmation) as part of the regulatory process.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). suppliers with NDC on PharmaCompass.
7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). GMP manufacturer or 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). GMP API supplier for your needs.
A 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CoA (Certificate of Analysis) is a formal document that attests to 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2).'s compliance with 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). specifications and serves as a tool for batch-level quality control.
7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CoA mostly includes findings from lab analyses of a specific batch. For each 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). may be tested according to a variety of international standards, such as European Pharmacopoeia (7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). EP), 7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). JP (Japanese Pharmacopeia) and the US Pharmacopoeia (7-CHLORO-4-((4-(DIETHYLAMINO)-1-METHYLBUTYL)AMINO)QUINOLINE PHOSPHATE (1:2). USP).